2-Year Effects of Alz-801/Valiltramiprosate on Plasma Fluid Biomarkers, Volumetric MRI Biomarkers & Cognition Support Disease Modification In APOE4 Carriers With Early Alzheimer’s Disease
Time: 11:00 am
day: Clinical & Commercial Track AM
Details:
- Evaluating ALZ-801 in EAD (early Alzheimer’s Disease) patients that are APoE4 carriers as measured by fluid biomarkers e.g. p-tau 181, imaging and clinical outcomes
- Highlighting a disease modifying effect and dynamic biomarker analysis over a 2-year period
- Evaluating potential disease modifying effects of ALZ-801 as an oral anti-oligomer agent in phase 3 development that demonstrating safety and tolerability
